DDInter1594 DDInter1819
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Rilonacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Rilonacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dactinomycin
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rilonacept {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Rilonacept {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Rilonacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Rilonacept may lead to a major life threatening interaction when taken with Fingolimod
Rilonacept may lead to a major life threatening interaction when taken with Leflunomide